Exoxemis Exoxemis - Indications
Home Technology Indications Collaborations Company Publications Contact
Nosocosmial Infections Surgical Site Infection Biodefence
 
>

Nosocomial Infections

Multiple MPO formulations are in development for prevention of serious, and often resistant, hospital-acquired infections.

 
       
>

Surgical Site Infection Prevention

Our unique MPO formulation holds the promise of a breakthrough in surgical site infection prevention.
more >>

   
       
>

Biodefense

The MPO technology platform suggests the potential for use in preventing infections in conventional and biological attack situations.
more >>

   
       
>
E-mail Inquiries    
Nosocomial Infections

The unique characteristics of MPO and EPO (rapid cidal action, broad-spectrum activity, and unique mechanism of action) are especially well-suited for preventing and treating the most serious types of nosocomial infections.

The incidence of nosocomial (or hospital-acquired) infections is estimated at 2 million cases annually, with 50% - 60% of those cases caused by antibiotic-resistant pathogens. The costs of nosocomial infections in the US are estimated at close to $6 billion annually with treatment costs for antibiotic-resistant nosocomial infections alone estimated at $1.3 billion dollars.


Incidence and resistant infections increase

Nosocomial infections, including surgical site infections, urinary tract infections, and ventilator-associated pneumonia, are increasing due to the aging of the population and treatment of older and more immunocompromised patients in hospital settings.

These infections are caused by a changing profile of pathogens, which are becoming increasingly resistant to available drugs. While bacterial resistance is the major threat, viral and fungal resistance is expected to become more important. Few, if any, drugs are available to effectively address these rapidly emerging problems. The Exoxemis MPO technology platform offers an alternative to traditional methods of preventing nosocomial infection without contributing to antimicrobial resistance.